Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of TAVO101 in Healthy Subjects
NCT05298046Phase 1Completed
- Sponsor
- Tavotek Biotherapeutics
- Start
- May 2022
- Primary completion
- Jun 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Tavo101 in atopic dermatitis (AD), asthma and chronic obstructive pulmonary disease (COPD) (4 arms), sponsored by Tavotek Biotherapeutics. Primary endpoints: Severity of Adverse Effects, Changes in oral or tympanic temperature and 3 more. Started May 2022; status: completed.
02
Drugs
Tavo101
03
Conditions
atopic dermatitis (AD)asthmachronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT05298046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05298046.